[1] CHO N H, SHAW J E, KARURANGA S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138:271-281. doi:  10.1016/j.diabres.2018.02.023
[2] SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183:109-119.
[3] DAVIES M J, D'ALESSIO D A, FRADKIN J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD). Diabetes Care. 2018 Dec;41(12): 2669-2701.
[4] MEIER J J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus[J]. Nat Rev Endocrinol, 2012, 8(12):728-742. doi:  10.1038/nrendo.2012.140
[5] 陆菊明. 《中国T2DM防治指南(2020年版)》读后感[J]. 中华糖尿病杂志, 2021, 13(4):301-304. doi:  10.3760/cma.j.cn115791-20210307-00135
[6] ELSAYED N A, ALEPPO G, ARODA V R, et al. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023[J]. Diabetes Care, 2023, 46(Suppl 1):S140-S157.
[7] DAVIES M J, ARODA V R, COLLINS B S, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association(ADA)and the European association for the study of diabetes(EASD)[J]. Diabetes Care, 2022, 45(11):2753-2786. doi:  10.2337/dci22-0034
[8] 谢永军. 药品不良反应信号检测方法研究进展[J]. 医药前沿, 2012(30):7-8. doi:  10.3969/j.issn.2095-1752.2012.30.002
[9] 黄佳, 钟薇, 王浩, 等. 基于美国FAERS数据库的恩美曲妥珠单抗不良事件信号挖掘与分析[J]. 中国医院药学杂志, 2022, 42(1):49-53.
[10] DRUCKER D J, NAUCK M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet, 2006, 368(9548):1696-1705. doi:  10.1016/S0140-6736(06)69705-5
[11] ARD J, FITCH A, FRUH S, et al. Weight loss and maintenance related to the mechanism of action of glucagon-like Peptide1 receptor agonists[J]. Adv Ther, 2021, 38(6):2821-2839. doi:  10.1007/s12325-021-01710-0
[12] BLEVINS T, PULLMAN J, MALLOY J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2011, 96(5):1301-1310. doi:  10.1210/jc.2010-2081
[13] DRUCKER D J, BUSE J B, TAYLOR K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study[J]. Lancet, 2008, 372(9645):1240-1250. doi:  10.1016/S0140-6736(08)61206-4
[14] GUPTA V. Glucagon-like peptide-1 analogues: an overview[J]. Indian J Endocrinol Metab, 2013, 17(3):413-421. doi:  10.4103/2230-8210.111625
[15] DAVIDSON J A, NIKKEL C, GRIMM M. Exenatide once weekly: opportunities in the primary care setting[J]. Postgrad Med, 2013, 125(3):68-78. doi:  10.3810/pgm.2013.05.2662
[16] KOLTERMAN O G, KIM D D, SHEN L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus[J]. Am J Health Syst Pharm, 2005, 62(2):173-181. doi:  10.1093/ajhp/62.2.173
[17] 徐涛. 糖尿病患者自行皮下注射胰岛素的教育与护理[J]. 中国社区医师, 2014, 30(25):138-139. doi:  10.3969/j.issn.1007-614x.2014.25.89
[18] CURE P, PILEGGI A, ALEJANDRO R. Exenatide and rare adverse events[J]. N Engl J Med, 2008, 358(18): 1969-1970;discussion 1971-1972.
[19] 胡方圆, 叶小飞, 翟映红, 等. 免疫抑制剂Cemiplimab的药物毒性: 基于FARES数据库的真实世界研究[J]. 中国药物警戒, 2020, 17(8):480-486.